Investig Clin Urol
Investig Clin Urol
Country: Unknown
Publisher: Unknown
Publication Period: Unknown
318
Papers in Database
Journal Information
Publication Details
Additional Information
Subject Term Count: 1
Last Updated: Aug 05, 2025
Recent Papers
View All 318 Papers2023 Korean Association of Urogenital Tract Infection and Inflammation guidelines for gonococcal infection.
Yang HJ, Lee HM, Lee SJ, Choi JB, Bae S, Jung JH, Kang TW, Hwang EC.
2023 Korean sexually transmitted infections guidelines by the Korean Association of Urogenital Tract Infection and Infl…
Choi CI, Lee SJ, Choi JB, Kim TH, Lee JW, Kim JM, Bae S.
2023 Korean sexually transmitted infections guidelines for non-gonococcal bacterial infection (chlamydia, syphilis, etc…
Choi J, Choi JB, Bae S, Lee CH, Shin YS, You D, Lee JY, Lee SJ, Lee KW.
2023 Korean sexually transmitted infections treatment guidelines for <i>Mycoplasma genitalium</i> by KAUTII.
Lee SJ, Choi JB, Bae S, Na SW, Jung HD, Jung HJ, Jung SI, Song PH, Lee G.
Clinical outcome and safety of holmium laser prostate enucleation after transrectal prostate biopsies for benign prosta…
Choi SM, Kang CS, Kim DH, Choi JH, Lee C, Jeh SU, Kam SC, Hwa JS, Hyun JS.
Histological and morphological development of the prepuce from birth to prepubertal age.
Erdem E, Caliskan MK, Karagul MI, Akbay E, Coskun Yilmaz B, Aygun YC.
<i>COL6A1</i> expression as a potential prognostic biomarker for risk stratification of T1 high grade bladder cancer: U…
Kim K, Byun YJ, Zheng CM, Moon S, Jo SJ, Kang HW, Kim WT, Choi YH, Moon SK, Kim WJ, Piao XM, Yun SJ.
Pediatric obesity and development of the penis and testis.
Lee D, Chung JM, Lee SD.
Progression-directed therapy in patients with oligoprogressive castration-resistant prostate cancer.
Lee JN, Kim MY, Kang JH, Kang JK, Chung JW, Ha YS, Choi SH, Kim BS, Kim HT, Kim TH, Yoo ES, Kim SH,…
Propensity score-matched analysis comparing perioperative, functional, and safety outcomes between thulium fiber laser …
Kamalov AA, Sorokin NI, Dzitiev VK, Strigunov AA, Nesterova OY, Bondar IV.